Latest news

Heberprot-P, a revolutionary treatment brings hope

The use of the medication Heberprot-P with some 290,000 patients, in twenty countries, has demonstrated the possibility of ensuring the healing of open wounds, ischemic ulcers, and those caused by diabetic foot disease, increasing the formation of granulation tissue, and thus reducing the need for amputation. The medicine, created at Cuba’s Genetic Engineering and Biotechnology […]

U.S. and Cuban companies reach agreement on Heberprot-p

Cuban enterprise Heber Biotec and U.S. company Mercurio Biotec have agreed to work together to make Heberprot-P – a Cuban developed medication to treat diabetic foot ulcers – available to patients in the U.S., once it has been approved by the country’s Food and Drug Administration (FDA). Given the success of the product and following […]

Heberprot-p Might Soon Be Available for US Patients

Cuban enterprise Heber Biotec and U.S. company Mercurio Biotec have agreed to work together to make Heberprot-P —a Cuban developed medication to treat diabetic foot ulcers— available for patients in the U.S., once it has been approved by the country’s Food and Drug Administration (FDA). Given the success of the product and following the Memorandum […]

see more

Our facts

Patients benefited in Cuba
75000
Patients benefited in the world
270000
Amputations in Cuba per year
920
Total patents granted
20

National program

weekly reports

Our social profiles

Controlling diabetes Congress 2018

Heberprot-P. Global situation of diabetes